menu
    • menu
    [{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Italian Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Sodium\/potassium\/chloride cotransporter","graph1":"Neurology","graph2":"Discovery","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Italian Institute of Technology","highestDevelopmentStatusID":"2","companyTruncated":"IAMA Therapeutics \/ Italian Institute of Technology"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IAMA-6","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IAMA-6","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"PsychoGenics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Therapeutics \/ PsychoGenics"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"PsychoGenics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Therapeutics \/ PsychoGenics"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Sapienza University of Rome","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"IAMA-6","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Sapienza University of Rome","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Therapeutics \/ Sapienza University of Rome"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"IAMA-6","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Therapeutics \/ Evotec"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IAMA-6","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IAMA-6","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IAMA Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by IAMA Therapeutics

    Menu

    IAMA Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IAMA Doses First Subject in Phase 1 Study of IAMA-6 for Autism

                            Details : IAMA-6 is an orally administered small molecule targeting NKCC1 to inhibit neuronal hyperexcitability. It is in phase 1 trials for Autism and Epilepsy.

                            Brand Name : IAMA-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 23, 2024

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA...

                            Details : IAMA-6 is an orally administered small molecule therapeutic targeting NKCC1. Its clinical trial application is approved after the preclinical studies for the treatment of autism and epilepsy.

                            Brand Name : IAMA-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec

                            Details : Evotec will provide IAMA with preclinical and clinical services to support the anticipated Phase 1 clinical trial to investigate IAMA's lead program IAMA-6, a small molecule therapeutic targeting NKCC1 for the treatment of autism and epilepsy.

                            Brand Name : IAMA-6

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 02, 2023

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Sapienza University of Rome

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy

                            Details : The collaboration aims to investigate the efficacy of selective chloride modulator, IAMA-6, in reducing neuronal excitability and hippocampal activity in human tissue with epilepsies and neurodevelopmental disorders, including Dravet syndrome, FCD, and R...

                            Brand Name : IAMA-6

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 10, 2023

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Sapienza University of Rome

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : PsychoGenics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome

                            Details : PsychoGenics will evaluate the anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which restore the physiological hyperpolarizing and inhibitory GABAergic transmission in a preclinical model of Dravet syndrome.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : PsychoGenics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : PsychoGenics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a S...

                            Details : Under the agreement, PsychoGenics will evaluate the preclinical anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which aims to reduce intracellular chloride concentration and restore the physiological hyperpolarizing and inhibitory GAB...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 25, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : PsychoGenics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience ...

                            Details : IAMA-6 is a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission.

                            Brand Name : IAMA-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2022

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry

                            Details : IAMA-6 is a preclinical stage, a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission.

                            Brand Name : IAMA-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 24, 2022

                            Lead Product(s) : IAMA-6

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            IAMA Therapeutics

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Italian Institute of Technology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neurosci...

                            Details : Under the collaboration with the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), they will design and profile new classes of compounds targeting cation cotransporters in the CNS area.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 29, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Italian Institute of Technology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth